Trial Profile
A Phase I Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2015
Price :
$35
*
At a glance
- Drugs DT388 GM CSF (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2012 New trial record